Skip to content

Search

Clinical development strategy for a candidate group A streptococcal vaccine

This review outlines a clinical development strategy detailing the phases of development required for registration of a candidate Group A streptococci vaccin

Disparity in Mortality From Rheumatic Heart Disease in Indigenous Australians

This study was undertaken to provide a comprehensive examination of rheumatic heart disease mortality rates and trends in Indigenous Australians.

Myositis complicating benzathine penicillin-G injection in a case of rheumatic heart disease

A 7-year old boy developed myositis secondary to intramuscular injection of benzathine penicillin-G in the context of secondary prophylaxis for RF

Are minor echocardiographic changes associated with an increased risk of acute rheumatic fever or progression to rheumatic heart disease?

We aimed to determine the significance of minor heart valve abnormalities, including Borderline RHD, in predicting the future risk of acute rheumatic fever.

The stark reality of rheumatic heart disease

This editorial refers to ‘Characteristics, complications, and gaps in evidence-based interventions in rheumatic heart disease: the Global Rheumatic Heart...

Rheumatic heart disease in Indigenous children in northern Australia: Differences in prevalence and the challenges of screening

This study compared regional differences in the prevalence of rheumatic heart disease in Indigenous Australian children, and describes the logistical and...

Development of Group A streptococcal vaccines: an unmet global health need

This review provides an update on the current status of Group A Streptococcus vaccine development, & describes global efforts to accelerate the development...

Evolution, Evidence and Effect of Secondary Prophylaxis Against Rheumatic Fever

The association between group A streptococcal infection and rheumatic fever (RF) was established in the early 20th century.